| Indicators | Browse All

Molecular Partners AG (MOLN)

Healthcare | Biotechnology | Schlieren, Switzerland | NasdaqGS
4.01 USD

Short-term:★★⯪☆☆Long-term:★☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 3:29 a.m. EDT

The immediate outlook is flat due to a lack of clear directional momentum, though the stock recently tested resistance near $4.29 with buyers showing some interest. However, the long-term picture is severely compromised by a brutal four-year price trajectory where the asset has lost over 81% of its value, driven by three consecutive years of negative annual returns ending with a sharp 46% drop last year. While analysts project a massive 200% upside to targets around $11-$12, this is a speculative bet on future clinical milestones rather than a reflection of current business health, evidenced by negative earnings, negative free cash flow, and a return on equity of nearly -60%. There is no dividend income to offset these risks, making this a high-risk venture play rather than an investment.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.039888
AutoARIMA0.056074
AutoETS0.056437
MSTL0.060812
MSTL_1260.105024

Forecast horizon: 60 days | Selected: AutoTheta

Forecast Reliability
Score 35%
H-stat 2.57
Ljung-Box p 0.000
Jarque-Bera p 0.521
Excess Kurtosis -0.72
Attribute Value
Sector Healthcare
Debt to Equity Ratio 4.885
Market Cap 150,416,016
Forward P/E -15.50
Beta 0.67
Website https://www.molecularpartners.com

Info Dump

Attribute Value
52 Week Change 0.12324929
Address1 Wagistrasse 14
All Time High 32.04
All Time Low 3.32
Ask 4.01
Ask Size 1
Average Analyst Rating 1.4 - Strong Buy
Average Daily Volume10 Day 10,560
Average Daily Volume3 Month 6,486
Average Volume 6,486
Average Volume10Days 10,560
Beta 0.673
Bid 3.91
Bid Size 1
Book Value 2.2580907
City Schlieren
Compensation As Of Epoch Date 1,767,139,200
Country Switzerland
Crypto Tradeable 0
Currency USD
Current Price 4.0099
Current Ratio 9.425
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 4.0099
Day Low 4.0099
Debt To Equity 4.885
Earnings Call Timestamp End 1,741,345,140
Earnings Call Timestamp Start 1,741,345,140
Earnings Timestamp End 1,773,345,600
Earnings Timestamp Start 1,773,345,600
Ebitda -51,890,000
Ebitda Margins 0.0
Enterprise To Ebitda -1.445
Enterprise Value 74,992,016
Eps Current Year -1.42
Eps Forward -0.25862262
Eps Trailing Twelve Months -1.92
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 41 44 755 77 07
Fifty Day Average 3.98146
Fifty Day Average Change 0.028439999
Fifty Day Average Change Percent 0.0071431077
Fifty Two Week Change Percent 12.324929
Fifty Two Week High 5.36
Fifty Two Week High Change -1.3501
Fifty Two Week High Change Percent -0.25188434
Fifty Two Week Low 3.41
Fifty Two Week Low Change 0.5999
Fifty Two Week Low Change Percent 0.17592375
Fifty Two Week Range 3.41 - 5.36
Financial Currency CHF
First Trade Date Milliseconds 1,623,850,200,000
Float Shares 19,918,428
Forward Eps -0.25862262
Forward P E -15.504831
Free Cashflow -25,200,500
Full Exchange Name NasdaqGS
Full Time Employees 134
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Gross Profits -36,662,000
Has Pre Post Market Data 1
Held Percent Insiders 0.0
Held Percent Institutions 0.095769994
Implied Shares Outstanding 37,511,163
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-06-16
Is Earnings Date Estimate 0
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Long Name Molecular Partners AG
Market us_market
Market Cap 150,416,016
Market State REGULAR
Max Age 86,400
Message Board Id finmb_32677064
Most Recent Quarter 1,774,915,200
Net Income To Common -58,024,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 147,402,530
Number Of Analyst Opinions 5
Open 3.9
Operating Cashflow -48,420,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 41 44 755 77 00
Previous Close 4.0099
Price Eps Current Year -2.8238733
Price Hint 4
Price To Book 1.7757922
Profit Margins 0.0
Quick Ratio 9.215
Quote Source Name Delayed Quote
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.4
Region US
Regular Market Change 0.0
Regular Market Change Percent 0.0
Regular Market Day High 4.0099
Regular Market Day Low 4.0099
Regular Market Day Range 4.0099 - 4.0099
Regular Market Open 3.9
Regular Market Previous Close 4.0099
Regular Market Price 4.0099
Regular Market Time 1,783,972,800
Regular Market Volume 74
Return On Assets -0.28816998
Return On Equity -0.59014
Sand P52 Week Change 0.20365608
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 37,511,163
Shares Percent Shares Out 0.0
Shares Short 1,751
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 10,189
Short Name Molecular Partners AG
Short Percent Of Float 0.0001
Short Ratio 0.24
Source Interval 15
Symbol MOLN
Target High Price 16.986532
Target Low Price 3.6636891
Target Mean Price 11.056733
Target Median Price 11.945088
Total Cash 78,768,000
Total Cash Per Share 2.1
Total Debt 3,344,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.92
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 4.18452
Two Hundred Day Average Change -0.17461967
Two Hundred Day Average Change Percent -0.04172992
Type Disp Equity
Volume 74
Website https://www.molecularpartners.com
Zip 8,952